EURETINA industry previews: Beacon Therapeutics, Nanoscope Therapeutics and Valitor
Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies
Navigating the dangers of oculofacial surgery
Jeremiah Tao, MD, FACS, used his Egyptian Ophthalmological Society keynote to explore complex and costly challenges in oculofacial surgery
Ashvattha Therapeutics, Clearside Biomedical, ZEISS preview EURETINA presentations
Clinical leaders including Susan Schneider, MD; Lejla Vajzovic, MD; and Harvey Uy, MD, will share new clinical findings
Progression rates vary in subtypes of geographic atrophy lesions
An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration
The Eye Care Network's clinical advisors will present at EURETINA
Where to find members of our editorial board at this year's European Society of Retina Specialists Congress
What to expect at this year's European Society of Retina Specialists (EURETINA) Congress
Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France
Keys to optimising phaco efficiency
New support offers a streamlined experience for surgeons and patients
European Commission issues CE mark for Zeiss CIRRUS PathFinder AI tool
The clinical support system integrates artificial intelligence into OCT interpretation workflow
Green spaces may have "protective effect" against dry eye disease
Patients with higher exposure to nature and green spaces were significantly less likely to experience dry eye, investigators reported
Starting from scratch on neovascular age-related macular degeneration
AMD treatment may become unrecognisable as gene therapies evolve
Québec announces faricimab (Vabysmo, Roche) will be funded for macular oedema secondary to RVO
The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications
First clinical results demonstrate efficacy of VOY-101, a novel gene therapy for GA
A 12-month follow-up indicated no dose limiting toxicity and no ocular or systemic adverse effects
Clinicians keep their eyes on wartime ocular trauma
Every day brings a new challenge for surgeons in low-resource areas and conflict zones
Patient outcomes in retinoblastoma impacted by parents' interventional delays
Salvation of ocular tissues and visual acuity are dependent on early diagnosis, investigators emphasised
Recap: The future of imaging is out of this world
Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond
Australian biotech firm Mirugen secures major funding for cell reprogramming therapy
New financing will support the company's lead retinitis pigmentosa programme, among other projects
Eyeing the brain: How ocular mitochondrial disease may predict dementia risk
Consistent trends across prevalence, incidence, odds and time-to-event models suggest ocular mitochondrial disease may indicate neurodegenerative risk
Sandoz will license Lupin's ranibizumab biosimilar in Europe, other select regions
Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries
German case study illustrates systemic presentation of tubulointerstitial nephritis and uveitis
An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation
Helping patients navigate the unsolved mysteries of genetic testing
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases
Alcon announces acquisition of STAAR Surgical, EVO ICL lenses
The transaction is anticipated to close in 6 to 12 months subject to customary closing conditions and regulatory approval
NICE announces UK approval of idebenone for treatment of Leber hereditary optic neuropathy
In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment
A realistic view of diabetes remission: GLP-1 therapies and the future of diabetic retinopathy
GLP-1 therapies could impact long-term outcomes in diabetic retinopathy
Feasibility of artificial intelligence in leading glaucoma care
Can AI compete with the well-oiled machine of the contemporary clinic?
Managing and monitoring the global burden of retinoblastoma
Enhanced screenings and a unified registry could save vision and lives
Opus Genetics, Global RDH12 Alliance announce new collaboration
The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight
Topcon expands AI portfolio with Intelligent Retinal Imaging Systems acquisition
The IRIS is a cloud-based model that supports artificial intelligence-assisted diabetic retinopathy screening
Exonate announces CLEAR-DE trial for EXN407
Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy
Re-Vana Therapeutics and Boehringer Ingelheim announce collaboration, licensing partnership
The companies will focus their joint effort on extended-release therapies for ocular disease
Biomarkers of microvascular retinal perfusion indicating coronary heart disease
Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography
